Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

BACKGROUND: While novel drugs have been developed, docetaxel remains one of the standard initial systemic therapies for castration-resistant prostate cancer (CRPC) patients. Despite the excellent anti-tumor effect of docetaxel, its severe adverse effects sometimes distress patients. Therefore, it wo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Urol
Main Authors: Yamashita, Shimpei, Kohjimoto, Yasuo, Iguchi, Takashi, Koike, Hiroyuki, Kusumoto, Hiroki, Iba, Akinori, Kikkawa, Kazuro, Kodama, Yoshiki, Matsumura, Nagahide, Hara, Isao
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4802623/
https://ncbi.nlm.nih.gov/pubmed/27001073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-016-0133-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados